Germany: Service Agreement Immunogenesis Collaborates with Probiogen for Cell Line Development
Immunogenesis has entered into a Service Agreement with Probiogen. Under the terms of the contract, Probiogen will support Immunogenesis’ cell line development and also conduct large-scale manufacturing in its new facility.
Berlin/Germany – Probiogen has recently announced that Immunogenesis, a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for cell line development, process development and GMP manufacturing in 1,000 L bioreactor scale for their lead candidate in the field of Immuno-Oncology.
Immunogenesis’ first-in-class monoclonal antibody candidate with two different specificities resulted from R&D work at the MD Anderson Cancer Center, University of Texas. Using its Cho.right expression platform for high-titer cell line development, Probiogen will support the development and conduct large-scale manufacturing of Immunogenesis’ promising molecule in Probiogen’s new facility. Now, with 2 facilities in Berlin, Probiogen is prepared to accommodate the increased demand for manufacturing.
“We are very excited to enter the development and manufacturing phase with our lead candidate”, said Michael A. Curran, founder of Immunogenesis and associate professor at the MD Anderson Cancer Center. “And with Probiogen we found the right partner that has great scientific expertise and the ‘can-do’ mindset which we very much appreciate for this challenging step.”
Dr. Wieland Wolf, CEO of Probiogen: “It is great to be part of the transition of the molecule to the clinic, and we are looking forward to work together with Immunogenesis on the realisation of their project.”
No numbers were disclosed.